Invex Therapeutics (Australia) Probability of Future Stock Price Finishing Over 0.0628
| IXC Stock | 0.07 0.01 7.46% |
Invex |
Invex Therapeutics Target Price Odds to finish over 0.0628
The tendency of Invex Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above 0.06 in 90 days |
| 0.07 | 90 days | 0.06 | about 98.0 |
Based on a normal probability distribution, the odds of Invex Therapeutics to stay above 0.06 in 90 days from now is about 98.0 (This Invex Therapeutics probability density function shows the probability of Invex Stock to fall within a particular range of prices over 90 days) . Probability of Invex Therapeutics price to stay between 0.06 and its current price of 0.072 at the end of the 90-day period is about 17.13 .
Assuming the 90 days trading horizon Invex Therapeutics has a beta of 0.52. This usually indicates as returns on the market go up, Invex Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Invex Therapeutics will be expected to be much smaller as well. Additionally Invex Therapeutics has an alpha of 0.03, implying that it can generate a 0.03 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Invex Therapeutics Price Density |
| Price |
Predictive Modules for Invex Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Invex Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Invex Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Invex Therapeutics is not an exception. The market had few large corrections towards the Invex Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Invex Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Invex Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.03 | |
β | Beta against Dow Jones | 0.52 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.0074 |
Invex Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Invex Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Invex Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Invex Therapeutics has some characteristics of a very speculative penny stock | |
| Invex Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the revenue of 1.21 M. Net Loss for the year was (1.64 M) with profit before overhead, payroll, taxes, and interest of 459.08 K. | |
| Invex Therapeutics generates negative cash flow from operations | |
| About 68.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Invex Therapeutics Restructures Amid Clinical Trial Challenges - TipRanks |
Invex Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Invex Stock often depends not only on the future outlook of the current and potential Invex Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Invex Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 75.3 M | |
| Cash And Short Term Investments | 6 M |
Invex Therapeutics Technical Analysis
Invex Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Invex Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Invex Therapeutics. In general, you should focus on analyzing Invex Stock price patterns and their correlations with different microeconomic environments and drivers.
Invex Therapeutics Predictive Forecast Models
Invex Therapeutics' time-series forecasting models is one of many Invex Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Invex Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Invex Therapeutics
Checking the ongoing alerts about Invex Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Invex Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Invex Therapeutics has some characteristics of a very speculative penny stock | |
| Invex Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the revenue of 1.21 M. Net Loss for the year was (1.64 M) with profit before overhead, payroll, taxes, and interest of 459.08 K. | |
| Invex Therapeutics generates negative cash flow from operations | |
| About 68.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Invex Therapeutics Restructures Amid Clinical Trial Challenges - TipRanks |
Additional Tools for Invex Stock Analysis
When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.